Value Added Technology Co Ltd
Value Added Technology Co Ltd designs, develops, and sells advanced medical equipment and technology, primarily serving the healthcare sector.
Business. Value Added Technology Co Ltd (043150.KQ) is a South Korean company engaged in the Advanced Medical Equipment & Technology industry. The firm operates within the Healthcare Services & Equipment sector, focusing on the development and sale of advanced medical devices. It is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Analyst recommendations
3 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Value Added Technology Co Ltd (043150.KQ) is a South Korean company engaged in the Advanced Medical Equipment & Technology industry. The firm operates within the Healthcare Services & Equipment sector, focusing on the development and sale of advanced medical devices. It is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
The company maintains a strong liquidity position, with a current ratio of 3.1, indicating a solid ability to meet short-term obligations. However, its price-to-book ratio of 0.62 suggests that the market values the company below its book value, which may reflect investor skepticism or undervaluation. The company's free cash flow of 43,166,347,670 KRW supports operational flexibility and potential reinvestment.
Profitability metrics show a return on equity of 8.1% and a return on assets of 5.82%, which are below the industry median for advanced medical equipment and technology firms. The company's operating margin of 12.8% is also below the sector average, indicating potential inefficiencies or competitive pressures in its operations.
Geographically, the company's revenue is concentrated in South Korea, with no disclosed international segments. This concentration increases exposure to local economic and regulatory conditions. The company operates a single business segment, which limits diversification and may heighten risk in the event of sector-specific downturns.
The company's revenue growth is projected to remain stable, with a modest increase expected in the current fiscal year. Historical revenue growth has been steady, but the pace has slowed in recent quarters. The company's capital expenditure of -11,298,199,840 KRW indicates a reduction in investment, which may signal a shift in strategic focus or a response to market conditions.
Risk factors include a medium liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is low, with no significant dilution expected in the near term. The company's debt-to-equity ratio of 0.09 suggests a conservative capital structure, but the negative net cash position could become a concern if cash flow deteriorates.
Recent events include the release of the latest financial report, which showed a decline in capital expenditures and a stable share count. No major regulatory or legal issues were disclosed in the latest filings. The company's management has not indicated any significant strategic changes in the near term.
- The company has a strong current ratio of 3.1, indicating good short-term liquidity.
- The company's return on equity of 8.1% is below the industry median, suggesting room for improvement in profitability.
- Revenue is concentrated in South Korea, increasing exposure to local economic and regulatory conditions.
- The company's capital expenditures have declined, which may indicate a strategic shift or a response to market conditions.
- Analysts have a positive outlook, with a mean price target of 29,250 KRW and a mean recommendation of 1.67.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 3 445,00 |
| Revenue | —no estimate | —no estimate | 462,8B KRW |
| Operating income | —no estimate | —no estimate | 59,5B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Value Added Technology Co Ltd Market data — financials · 2026-05-26
- Value Added Technology Co Ltd Market data — analyst estimates · 2026-05-26